DEF 14A: Pulse Biosciences Seeks Shareholder Approval for Equity Plan Boost

Pulse Biosciences will hold a special meeting to approve increasing its equity incentive plan by 2 million shares and ratify 1.1 million previously granted options.

Summary

• A special meeting of stockholders will be held virtually on September 30, 2025, at 4:00 p.m. Eastern Time.
• Stockholders will vote on two proposals: amending the 2017 Equity Incentive Plan and ratifying previously granted stock options.
• Proposal 1 seeks to increase the number of shares authorized for issuance under the Equity Plan by 2,000,000 shares.
• Proposal 1 also aims to change the Equity Plan's definition of 'Consultant' to include employees engaged through an employer of record.
• Proposal 2, contingent on Proposal 1's approval, seeks to ratify options awarded on August 9, 2024, and January 21, 2025, totaling 1,100,000 shares of common stock.
• The Board of Directors unanimously recommends a 'FOR' vote on both proposals.
• As of August 25, 2025, there were zero shares available for issuance under the existing Equity Plan, necessitating the proposed increase.
• The company had 67,295,847 shares of common stock outstanding and entitled to vote as of the August 25, 2025 record date.

Sentiment

Score: 7

Explanation: The filing indicates proactive management of employee and director incentives, which is positive for long-term growth and retention. The need for additional shares is a sign of ongoing compensation needs and potentially growth. However, the proposed increase in shares and ratification of options will lead to some level of dilution for existing shareholders, which is a minor negative. The performance-based vesting for some consultants is a strong positive, aligning incentives with significant value creation. Overall, the sentiment is positive as it addresses critical talent management and incentive alignment.

Positives

• Increasing the share pool allows the company to continue attracting, retaining, and motivating highly-qualified employees and non-employee directors through equity compensation.
• The change in the 'Consultant' definition provides flexibility to grant equity awards to employees engaged via third-party payrolling services, broadening the talent pool for equity incentives.
• Ratification of previously granted options ensures key executive, directors, and consultants are properly incentivized for their service and future contributions.
• Performance-based vesting conditions for some consultant awards (e.g., market capitalization targets of $4B and $5B) align incentives with significant company growth.

Negatives

• The approval of Proposal 1 will result in an increase of 2,000,000 shares available for issuance, which could lead to dilution for existing shareholders.
• The ratification of 1,100,000 options, combined with the additional 2,000,000 shares, represents a substantial increase in potential dilution.

Risks

• If Proposal 1 is not approved, the company will lack sufficient shares under its Equity Plan to support intended compensation programs, potentially hindering its ability to attract and retain talent.
• If Proposal 1 is not approved, Proposal 2 (ratification of 1,100,000 options) will not be approved, rendering those awards void and potentially impacting morale and retention of key personnel.
• Broker non-votes will not be counted for quorum purposes for these non-routine matters, and abstentions will act as a vote against both proposals, increasing the risk of non-approval if shareholder engagement is low.

Future Outlook

The company anticipates that if both Proposal 1 and Proposal 2 are approved, the pool of available shares under the Equity Plan will consist of approximately 250,000 shares at the end of the third quarter of 2025. The Board believes that continuing to offer equity compensation will enhance its ability to attract, retain, and motivate highly-qualified employees and non-employee directors for future years.

Management Comments

• Our Board of Directors believes that the success of the Company is largely dependent on its ability to attract, retain and motivate highly-qualified employees and non-employee directors, and that by continuing to offer them the opportunity to acquire or increase their proprietary interest in the Company, the Company will enhance its ability to attract, retain and motivate such persons.

Industry Context

The proposed amendments to the equity incentive plan are consistent with common practices in the biotechnology and medical device industries, where equity compensation is a critical tool for attracting and retaining top talent, particularly in early-stage or growth-oriented companies. The ability to grant equity to consultants engaged through third-party payrolling services reflects a growing trend in flexible workforce management within specialized fields, allowing companies to access expertise without traditional employment structures. The market capitalization vesting targets for certain consultant awards are also a common mechanism to align executive and key personnel incentives with significant shareholder value creation, a practice frequently observed in high-growth sectors.

Comparison to Industry Standards

• The use of an evergreen provision for annual increases in the share pool (least of 1,200,000 shares, 4% of outstanding shares, or Board-determined number) is a standard mechanism in equity incentive plans across many industries, including biotech, to ensure a continuous supply of shares for compensation without frequent shareholder votes.
• The annual grant limits for stock options (400,000 shares) and restricted stock (250,000 shares) per participant are typical for plans designed to comply with Section 162(m) of the U.S. tax code, although the performance-based compensation exemption has largely been removed, the 'Grandfather Rule' still applies to certain existing contracts.
• The inclusion of market capitalization targets ($4 billion and $5 billion) for vesting of consultant options is a robust performance-based incentive, comparable to those seen in high-growth technology and biotech companies aiming for significant valuation milestones. For example, similar performance hurdles are often tied to executive compensation in companies like Moderna or BioNTech during their growth phases, linking compensation directly to substantial increases in shareholder value.

Corporate Governance

Related Party Transactions

• Robert W. Duggan, who beneficially owns 72.3% of the common stock, is married to Dr. Mahkam Zanganeh, a director who received a grant of 200,000 options subject to ratification. While they may be deemed to have acquired beneficial ownership of each other's securities upon marriage, both disclaim beneficial ownership of the other's holdings except to the extent of pecuniary interest.

Stakeholder Impact

• **Shareholders:** Potential dilution from the increased share pool and ratified options. However, the ability to attract and retain key talent through equity compensation could lead to long-term value creation.
• **Employees and Directors:** Direct positive impact through continued access to equity compensation, enhancing their proprietary interest in the company and aligning their incentives with company performance.
• **Consultants:** The expanded definition of 'Consultant' allows for equity awards to a broader group of service providers, and the ratification of options provides significant incentives, including performance-based vesting tied to market capitalization.

Next Steps

• Stockholders will vote on Proposal 1 and Proposal 2 at the Special Meeting on September 30, 2025.
• Preliminary results will be announced at the Special Meeting.
• Final results will be published in a Current Report on Form 8-K filed with the SEC after the Special Meeting.

Key Dates

Recommendation

The filing details routine corporate governance matters related to an equity incentive plan. While the increase in authorized shares and ratification of options could lead to some dilution, these actions are necessary for the company to attract and retain key talent, which is crucial for long-term growth in the biotech sector. The performance-based vesting for some awards is a positive alignment of incentives. Given that these are standard operational adjustments rather than significant financial or strategic announcements, the filing is unlikely to cause a substantial immediate shift in the stock price. A 'hold' recommendation reflects the neutral to slightly positive implications for the company's operational stability and talent management, without suggesting a strong catalyst for immediate price appreciation or depreciation based solely on this filing.

Keywords

Equity Incentive Plan, Stock Options, Shareholder Meeting, Proxy Statement, Executive Compensation, Corporate Governance, Stock Dilution, Employee Retention, Consultant Definition, NASDAQ